News

(Singapore, 11.06.2026)DKSH has entered into a strategic distribution partnership with biotechnology company BridgeBio to support the regulatory evaluation and…

AbstractTransthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly recognized because of improved diagnostic modalities and disease-modifying therapy. We report…

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive infiltrative cardiomyopathy caused by myocardial deposition of misfolded transthyretin, leading to…

Abstract and FiguresImportance Timely diagnosis of transthyretin cardiac amyloidosis (ATTR-CM) is critical for early treatment to reduce morbidity and mortality,…

Study OverviewBrief SummaryTransthyretin amyloid cardiomyopathy (ATTR-CM) is a heart condition caused by a protein called transthyretin (TTR) building up as amyloid…

SINGAPORE, June 11, 2026 /PRNewswire/ -- DKSH entered a strategic distribution partnership with BridgeBio to support regulatory evaluation and potential patient…

Higher blood levels of fibroblast growth factor 23 (FGF23) — a bone-derived hormone — are associated with higher levels of established markers of heart damage and…

AbstractBackground: Advances in diagnostic criteria for transthyretin cardiac amyloidosis (ATTR-CM) and expanded insurance coverage for bone scintigraphy have…

AbstractObjectiveTo assess the neuropathic burden and quality-of-life impact in patients with wild-type transthyretin amyloidosis (wtATTR) using standardized…

Efficacy of acoramidis in transthyretin amyloid cardiomyopathy with and without atrial fibrillation: results from ATTRibute-CM. (Top) In this post hoc analysis of…